title: Glycine amides as PPARalpha agonists.
abstract: The design, synthesis and pharmacological properties of a novel class of PPARalpha agonists is described. Compound 2 is a novel, potent and specific glycine amide with oral bioavailability in rodents. The compound is active in vivo and alters plasma lipids in hAPO-A1 transgenic mice after oral administration.
authors.affiliation: Department of Medicinal Chemistry, Bayer Healthcare, Bayer-Schering Pharma, D-42096 Wuppertal, Germany. Klaus.Urbahns@astrazeneca.com
authors.forename: Klaus
authors.initials: K
authors.lastname: Urbahns
authors.forename: Michael
authors.initials: M
authors.lastname: Woltering
authors.forename: Susanne
authors.initials: S
authors.lastname: Nikolic
authors.forename: Josef
authors.initials: J
authors.lastname: Pernerstorfer
authors.forename: Hilmar
authors.initials: H
authors.lastname: Bischoff
authors.forename: Elke
authors.initials: E
authors.lastname: Dittrich-Wengenroth
authors.forename: Klemens
authors.initials: K
authors.lastname: Lustig
mesh_terms: D000818:Animals; D001682:Biological Availability; D005998:Glycine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D051379:Mice; D008822:Mice, Transgenic; D047493:PPAR alpha / Q000819:agonists*; D013329:Structure-Activity Relationship
chemical_list: D047493:PPAR alpha; C018556:glycine amide; D005998:Glycine